- Should pharma be swinging bigger with AI? One top researcher wants to tryRIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Interna…Endpoints · 2mo ago↗ source
- GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readoutsGSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with…Endpoints · 2mo ago↗ source
- MPM has collected three China drugs for its ‘best of both worlds’ strategyMPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed thre…